Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8444708 | 0.88 | DHFR (0.49) | DHFR | |
| SCHEMBL7165726 | 0.88 | DHFR (0.52) | DHFR | |
| SCHEMBL8444709 | 0.81 | DHFR (0.47) | DHFR | |
| SCHEMBL8420248 | 0.80 | DHFR (0.47) | DHFR | |
| SCHEMBL5322113 | 0.78 | DHFR (0.59) | DHFR | |
| SCHEMBL5323442 | 0.78 | DHFR (0.58) | DHFR | |
| SCHEMBL8448168 | 0.78 | DHFR (0.60) | DHFR | |
| SCHEMBL27501803 | 0.78 | DHFR (0.60) | DHFR | |
| SCHEMBL8448171 | 0.78 | DHFR (0.60) | DHFR | |
| SCHEMBL8446677 | 0.78 | HDAC4 (0.49) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6016669-A | — | — | None | — | — | JP | disclosed |
| US-20030171376-A1 | Antiarthritic agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-0632038-A1 | METHOTREXATE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1995-01-04 | — | — | EP | disclosed |
| JP-H0616669-A | NEW METHOTREXATE DERIVATIVE | CHUGAI PHARMACEUT CO LTD | 1994-01-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171376-A1 | Antiarthritic agents | BCOR, RCOR1, IL4 | DHFR 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.